How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
54
CAPR Quote, Financials, Valuation and Earnings
Last price:
$21.89
Seasonality move
:
12.21%
Day range:
$21.83 - $23.00
52-week range:
$4.30 - $40.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
89.27x
P/B ratio:
11.93x
Volume:
972.9K
Avg. volume:
1.3M
1-year change:
44.01%
Market cap:
$1B
Revenue:
$22.3M
EPS (TTM):
-$1.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
-- | -$0.55 | -100% | -7.2% | $50.80 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$232.2M | $2.01 | 5.9% | 130.85% | $110.38 |
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
$14.3M | -$0.76 | -73.11% | -17.84% | $33.56 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.2500 |
|
INO
Inovio Pharmaceuticals, Inc.
|
-- | -$0.35 | 410.46% | -34.31% | $7.63 |
|
MYO
Myomo, Inc.
|
$10.4M | -$0.09 | -13.8% | -1168.66% | $5.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
$21.89 | $50.80 | $1B | -- | $0.00 | 0% | 89.27x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$81.85 | $110.38 | $1.8B | 50.20x | $0.00 | 0% | 2.00x |
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
$7.47 | $33.56 | $212.2M | 8.50x | $0.00 | 0% | 2.38x |
|
CATX
Perspective Therapeutics, Inc.
|
$3.7900 | $12.2500 | $281.7M | -- | $0.00 | 0% | 256.98x |
|
INO
Inovio Pharmaceuticals, Inc.
|
$1.63 | $7.63 | $112M | -- | $0.00 | 0% | 362.28x |
|
MYO
Myomo, Inc.
|
$0.84 | $5.00 | $32.3M | -- | $0.00 | 0% | 0.83x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
17.61% | -4.372 | 5.44% | 3.50x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.736 | 30.7% | 2.40x |
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
10.37% | 2.429 | 5.18% | 7.68x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INO
Inovio Pharmaceuticals, Inc.
|
435.62% | 1.704 | 7.99% | 0.74x |
|
MYO
Myomo, Inc.
|
45.68% | -2.417 | 35.87% | 1.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
-$494.7K | -$26.3M | -72.3% | -77.32% | -69.16% | -$23.7M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
$13.4M | -$15.6M | -24.78% | -27.98% | -110.37% | -$19.8M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INO
Inovio Pharmaceuticals, Inc.
|
-$749.7K | -$21.2M | -199.9% | -252.43% | -30140.49% | -$21.6M |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
Capricor Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CAPR or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of 10.59%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About CAPR or ANIP?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 132.07%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.38 which suggests that it could grow by 34.85%. Given that Capricor Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Capricor Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is CAPR or ANIP More Risky?
Capricor Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.875% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.
-
Which is a Better Dividend Stock CAPR or ANIP?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CAPR or ANIP?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 89.27x versus 2.00x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.89.27x -- -- -$24.6M ANIPANI Pharmaceuticals, Inc.2.00x 50.20x $227.8M $24.1M
-
Which has Higher Returns CAPR or ARCT?
Arcturus Therapeutics Holdings, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -95.02%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M ARCTArcturus Therapeutics Holdings, Inc.94.35% -$0.49 $250.5M -
What do Analysts Say About CAPR or ARCT?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 132.07%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $33.56 which suggests that it could grow by 349.2%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 ARCTArcturus Therapeutics Holdings, Inc.7 3 0 -
Is CAPR or ARCT More Risky?
Capricor Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.875% less volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.17%.
-
Which is a Better Dividend Stock CAPR or ARCT?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or ARCT?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 89.27x versus 2.38x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.89.27x -- -- -$24.6M ARCTArcturus Therapeutics Holdings, Inc.2.38x 8.50x $14.2M -$13.4M
-
Which has Higher Returns CAPR or CATX?
Perspective Therapeutics, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -12425.36%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About CAPR or CATX?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 132.07%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.2500 which suggests that it could grow by 223.22%. Given that Perspective Therapeutics, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 CATXPerspective Therapeutics, Inc.11 1 0 -
Is CAPR or CATX More Risky?
Capricor Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.875% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock CAPR or CATX?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or CATX?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Capricor Therapeutics, Inc.'s net income of -$24.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 89.27x versus 256.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.89.27x -- -- -$24.6M CATXPerspective Therapeutics, Inc.256.98x -- $209K -$26M
-
Which has Higher Returns CAPR or INO?
Inovio Pharmaceuticals, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -30140.49%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Inovio Pharmaceuticals, Inc.'s return on equity of -252.43%.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M INOInovio Pharmaceuticals, Inc.-- -$0.87 $2.3M -
What do Analysts Say About CAPR or INO?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 132.07%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 368.3%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 INOInovio Pharmaceuticals, Inc.2 2 0 -
Is CAPR or INO More Risky?
Capricor Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.875% less volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.618, suggesting its more volatile than the S&P 500 by 61.808%.
-
Which is a Better Dividend Stock CAPR or INO?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or INO?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Capricor Therapeutics, Inc.'s net income of -$24.6M is higher than Inovio Pharmaceuticals, Inc.'s net income of -$45.5M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 89.27x versus 362.28x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.89.27x -- -- -$24.6M INOInovio Pharmaceuticals, Inc.362.28x -- -- -$45.5M
-
Which has Higher Returns CAPR or MYO?
Myomo, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -36.3%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About CAPR or MYO?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 132.07%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 495.88%. Given that Myomo, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Myomo, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 MYOMyomo, Inc.4 0 0 -
Is CAPR or MYO More Risky?
Capricor Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.875% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.
-
Which is a Better Dividend Stock CAPR or MYO?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or MYO?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 89.27x versus 0.83x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.89.27x -- -- -$24.6M MYOMyomo, Inc.0.83x -- $10.1M -$3.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
62
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
60
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
